TcrossGlobal

TAVR with Self-Expandable Devices in Low-Risk Patients: 4-Year Follow-up of the EVOLUT Low Risk Trial

According to a 4-year follow-up of the EVOLUT Low Risk trial, TAVR with the Evolut platform had a lower 4-year rate of death/disabling stroke, compared to surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis at low risk for surgery. Dr. Michael J. Reardon, Methodist DeBakey Heart and Vascular Center, USA., presented at the Late-Breaking Clinical Trials session of TCT 2023.

The EVOLUT Low Risk trial enrolled a total of 1,468 patients with symptomatic severe aortic stenosis...

Continue reading this article

Select an option below:

Free Registration
Already have an account?
Log In

Introducing the main contents

Conference Reports

Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!

Complex PCI Cases

Features case reports on patients with complex lesions encountered in daily clinical practice.

Live Demonstration CoursesComing soon

In this section you will find live videos of catheter interventions for complex lesions.

What is TCROSS NEWS GLOBAL?

TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.

Learn more about TCROSS NEWS Global

This website is automatically translated using Google Translate.